Items where Author is "Roudi, R."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 20.

Article

Roviello, G. and Zanotti, L. and Cappelletti, M.R. and Gobbi, A. and Dester, M. and Paganini, G. and Pacifico, C. and Generali, D. and Roudi, R. (2018) Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? Clinical and Experimental Medicine, 18 (1). pp. 15-20.

Roviello, G. and Zanotti, L. and Cappelletti, M.R. and Gobbi, A. and Dester, M. and Paganini, G. and Pacifico, C. and Generali, D. and Roudi, R. (2018) Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? Clinical and Experimental Medicine, 18 (1). pp. 15-20.

Fathi, Z. and Mousavi, S.A.J. and Roudi, R. and Ghazi, F. (2018) Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients. PLoS ONE, 13 (7).

Syn, N.L.X. and Roudi, R. and Wang, L.Z. and Wang, L. and Loh, M. and Huang, Y. and Ou, S.-H.I. and Soong, R. and Drilon, A. and Wee, I. (2018) Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: A generic protocol. Cochrane Database of Systematic Reviews, 2018 (4).

Syn, N.L.X. and Roudi, R. and Wang, L.Z. and Wang, L. and Loh, M. and Huang, Y. and Ou, S.-H.I. and Soong, R. and Drilon, A. and Wee, I. (2018) Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: A generic protocol. Cochrane Database of Systematic Reviews, 2018 (4).

Fathi, Z. and Syn, N.L. and Zhou, J.-G. and Roudi, R. (2018) Molecular epidemiology of lung cancer in Iran: Implications for drug development and cancer prevention. Journal of Human Genetics, 63 (7). pp. 783-794.

Fathi, Z. and Syn, N.L. and Zhou, J.-G. and Roudi, R. (2018) Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention. Journal of Human Genetics. pp. 1-12.

Lam, W.S.-T. and Wang, L.Z. and Roudi, R. and Yong, W.-P. and Syn, N.L. and Sundar, R. (2018) Resisting resistance to cancer immunotherapy. Thoracic Cancer, 9 (5). pp. 507-508.

Lam, W.S.-T. and Wang, L.Z. and Roudi, R. and Yong, W.-P. and Syn, N.L. and Sundar, R. (2018) Resisting resistance to cancer immunotherapy. Thoracic Cancer, 9 (5). pp. 507-508.

Zhu, J. and Li, R. and Tiselius, E. and Roudi, R. and Teghararian, O. and Suo, C. and Song, H. (2017) Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database of Systematic Reviews, 2017 (12).

Zhu, J. and Li, R. and Tiselius, E. and Roudi, R. and Teghararian, O. and Suo, C. and Song, H. (2017) Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database of Systematic Reviews, 2017 (12).

Korourian, A. and Roudi, R. and Shariftabrizi, A. and Madjd, Z. (2017) MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Experimental Biology and Medicine, 242 (18). pp. 1842-1847.

Korourian, A. and Roudi, R. and Shariftabrizi, A. and Madjd, Z. (2017) MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Experimental Biology and Medicine, 242 (18). pp. 1842-1847.

Roudi, R. and Kalantari, E. and Keshtkar, A. and Madjd, Z. (2016) Accuracy of c-KIT in lung cancer prognosis; a systematic review protocol" instead of c-KIT expression in lung cancer prognostic evaluation - A systematic review protocol. Asian Pacific Journal of Cancer Prevention, 17 (2). pp. 863-866.

Erfani, E. and Roudi, R. and Rakhshan, A. and Sabet, M.N. and Shariftabrizi, A. and Madjd, Z. (2016) Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes. International Journal of Biological Markers, 31 (1). e53-e61.

Rasti, A. and Mehrazma, M. and Madjd, Z. and Keshtkar, A.A. and Roudi, R. and Babashah, S. (2016) Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: A systematic review protocol. BMJ Open, 6 (1).

Roudi, R. and Haji, G. and Madjd, Z. and Shariftabrizi, A. and Mehrazma, M. (2016) Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer;a tissue microarray analysis. Journal of Cancer Research and Therapeutics, 12 (2). pp. 1065-1069.

Roudi, R. and Madjd, Z. and Ebrahimi, M. and Najafi, A. and Korourian, A. and Shariftabrizi, A. and Samadikuchaksaraei, A. (2016) Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. Tumor Biology, 37 (9). pp. 11843-11859.

Roudi, R. and Ebrahimi, M. and Sabet, M.N. and Najafi, A. and Nourani, M.R. and Fomeshi, M.R. and Samadikuchaksaraei, A. and Shariftabrizi, A. and Madjd, Z. (2015) Comparative gene-expression profiling of CD133+ and CD133- D10 melanoma cells. Future Oncology, 11 (17). pp. 2383-2393.

Roudi, R. and Korourian, A. and Shariftabrizi, A. and Madjd, Z. (2015) Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes. Cancer Investigation, 33 (7). pp. 294-302.

This list was generated on Sun Sep 15 21:24:54 2019 +0430.